Reports of Practical Oncology and Radiotherapy最新文献

{"title":"Treatment of oropharyngeal cancer during the COVID-19 lockdown - outcomes for patients treated during the pandemic.","authors":"Niall O'Dwyer, Liam O'Connell, Darragh Browne, Bahareh Khosravi, Sinead Brennan, Fran Duane, John Armstrong, Oleksandr Boychak, Orla McArdle","doi":"10.5603/rpor.103236","DOIUrl":"https://doi.org/10.5603/rpor.103236","url":null,"abstract":"<p><strong>Background: </strong>The onset of the coronavirus disease 2019 (COVID-19) outbreak caused major interruptions to the entire healthcare network affecting referral, diagnosis and treatment pathways with the potential to affect cancer treatment outcomes. In Ireland a national lockdown was initiated in March 2020 involving a stay-at-home order with a limitation on travel, social interactions and closure of schools, universities and childcare facilities. We designed a retrospective study comparing treatment outcomes for patients with oropharyngeal cancer treated before and during the COVID pandemic.</p><p><strong>Materials and methods: </strong>All patients receiving radical radiotherapy for oropharyngeal cancer pre-COVID (July 17 - July 18) and during COVID (Mar 20 - Mar 21) were included. Patient and disease characteristics, diagnostic timelines, treatment delays and disease outcomes were extracted from the patient record. Disease free survival and overall survival were calculated for both groups.</p><p><strong>Results: </strong>159 oropharynx patients were included, 76 in the pre-COVID group (Group 1) and 83 in the pandemic group (Group 2). When comparing Group 1 and 2, respectively: There were no differences in human papilloma virus (HPV) status (74% <i>vs.</i> 71% p = 0.795) or Tumour-Node-Metastasis (TNM) overall stage [American Joint Committee on Cancer (AJCC) ed. 8]: (Stage 1: 25% <i>vs</i>. 45.8%, Stage 2: 28.9% <i>vs.</i> 18.1%, Stage 3: 21% <i>vs.</i> 15.7%, Stage 4: 25% <i>vs.</i> 20.5%, p = 0.268). Use of moderate hypofractionated regime increased during the pandemic (2.6% to 10.8%) and one patient omitted chemotherapy due to COVID-related reasons. There was no change in overall treatment times between groups with COVID-related sepsis accounting for one significant delay and one death during treatment. Overall survival at 2 years via Kaplan-Meier analysis; Group 1 cumulative proportion surviving at 2 years was 77% [95% confidence interval (CI): 67-86%] <i>vs</i>. 85% in Group 2 (95% CI: 77-93%, p = 0.35). The disease free survival at 2 years was 69% in Group 1 (95% CI: 59-80%) <i>vs.</i> 76% in Group 2 (95% CI: 67-85%, p = 0.567).</p><p><strong>Conclusion: </strong>In spite of challenges related to the COVID-19 pandemic, we have demonstrated that oropharyngeal cancer patients treatment standards and outcomes were maintained. We did not demonstrate any significant difference in overall survival and disease free survival at 2 years when compared to a similar group prior to the pandemic.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 5","pages":"606-613"},"PeriodicalIF":1.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698554/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Local chemotherapy with conjunctival bevacizumab injections in case of lymphoma tumor.","authors":"Piotr Fryczkowski","doi":"10.5603/rpor.102880","DOIUrl":"https://doi.org/10.5603/rpor.102880","url":null,"abstract":"","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 5","pages":"661-665"},"PeriodicalIF":1.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hippocampal protection during preventive cranial irradiation and neurocognitive functions in patients with small cell lung cancer.","authors":"Karolina Loga, Bartosz Wojcik, Anna Stanislawek, Anna Papis-Ubych, Lukasz Kuncman, Jacek Fijuth, Leszek Gottwald","doi":"10.5603/rpor.102617","DOIUrl":"https://doi.org/10.5603/rpor.102617","url":null,"abstract":"<p><strong>Background: </strong>In small cell lung cancer (SCLC), limiting the radiation dose in the hippocampus area during preventive cranial irradiation (PCI) can reduce nerve injury and cognitive decline. This study was done to compare changes in cognitive functions between hippocampal-protected (3D-H) and non-hippocampal-protected (3D) patients during PCI.</p><p><strong>Materials and methods: </strong>the study group included 113 patients with SCLC qualified to PCI divided in two subgroups: 3D-H (n = 74) and 3D (n = 39). Two diagnostic and screening tests, Mini-Mental State Examination (MMSE) Short Scale and Montreal Cognitive Assessment (MoCA) Scale, have been applied before the start of irradiation, immediately after and 3 months after PCI.</p><p><strong>Results: </strong>The doses delivered to the volume of the left and right hippocampus were similar and amounted to 12.00 Gy and 12.05 Gy, respectively. There were no differences between 3D-H and 3D groups in the MoCA and MMSE tests at any time point. In both groups the values in MoCA and MMSE scales differed between time points I, II and III. The patients in the 3D-H group were less likely than patients in 3D group to experience significant cognitive decline on the MoCA scale (p = 0.003), but not on the MMSE scale (p = 0.103).</p><p><strong>Conclusions: </strong>Following PCI, SCLC patients experience significant cognitive decline, even when the radiation dose in the hippocampal area is reduced. This trend continues for at least 3 months following the PCI. In hippocampal-protected patients significant cognitive decline assessed on the MoCA scale is less common than in non-hippocampal-protected patients.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 5","pages":"558-565"},"PeriodicalIF":1.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698556/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prehabilitation approaches for gastrointestinal cancer surgery: a narrative review.","authors":"Sergii Girnyi, Luigi Marano, Jaroslaw Skokowski, Piotr Mocarski, Witold Kycler, Gaetano Gallo, Agnieszka Dyzmann-Sroka, Karolina Kazmierczak-Siedlecka, Leszek Kalinowski, Tomasz Banasiewicz, Karol Polom","doi":"10.5603/rpor.103136","DOIUrl":"https://doi.org/10.5603/rpor.103136","url":null,"abstract":"<p><p>Gastrointestinal (GI) cancer patients undergoing surgery are particularly vulnerable to malnutrition, which can significantly impact surgical outcomes. Prehabilitation interventions encompassing nutritional, physical, and psychosocial support have gained attention for their potential to mitigate these risks. However, the efficacy of multidisciplinary prehabilitation programs in this context remains underexplored. This narrative review synthesizes existing literature to evaluate the effectiveness of prehabilitation interventions in improving outcomes for GI cancer patients undergoing surgery. Drawing on a comprehensive analysis of available evidence, the review examines the integration of nutritional, physical, and psychosocial interventions and explores the implications for clinical practice and future research. The review highlights the importance of standardized protocols and interdisciplinary collaboration in optimizing prehabilitation programs for GI cancer patients. It identifies gaps in current research, particularly regarding the synergistic effects of integrating various intervention modalities and the role of innovative strategies such as immunonutrition. Moreover, the review underscores the need for larger studies to assess the effectiveness of multimodal prehabilitation approaches and establish standardized outcome measures. In conclusion, despite advancements in understanding the importance of prehabilitation, significant gaps persist in the literature, warranting further research to refine prehabilitation protocols and improve perioperative outcomes for GI cancer patients. By addressing these research gaps and fostering interdisciplinary partnerships, future studies have the potential to enhance the effectiveness of prehabilitation interventions and optimize perioperative care in this population.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 5","pages":"614-626"},"PeriodicalIF":1.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endothelial progenitor cells as an angiogenic biomarker for the diagnosis and prognosis of lung cancer.","authors":"Fadi Najjar, Hassan Alsabe, Hussein Sabbagh, Ghassan Al-Massarani, Abdulmunim Aljapawe, Nissreen Alamalla, Issraa Banat, Adnan Ikhtiar","doi":"10.5603/rpor.102618","DOIUrl":"https://doi.org/10.5603/rpor.102618","url":null,"abstract":"<p><strong>Background: </strong>Angiogenesis is mediated by endothelial progenitor cells (EPCs) derived from bone-marrow. In this prospective study, we tried to investigate the clinical utility of circulating EPCs in lung cancer (LC) patients.</p><p><strong>Materials and methods: </strong>Flow cytometry technique was used to assess circulating EPCs according to the immuno-phenotype CD45^- CD34⁺ CD133⁺ CD146⁺ mononuclear cells. Sixty patients and 30 controls were included in this prospective study.</p><p><strong>Results: </strong>The mean of baseline EPC numbers was significantly higher in LC patients than in controls (p =0.003). Pretreatment EPC values were significantly correlated with primary tumor size (p = 0.05) and tumor response (p = 0.04). Receiver operating characteristics (ROC) curves were plotted to discriminate EPC numbers between patients and controls. Using ROC analysis, the optimal cutoff value was 125 cells/mL with a sensitivity and a specificity for baseline EPCs of 76.7% and 63.3%, respectively. According to this cutoff value, basal EPC values were significantly correlated with primary tumor size (p = 0.047) and response to chemotherapy (p = 0.034). High EPC levels were significantly associated with longer progression-free survival (PFS) and overall survival (OS) duration (p = 0.0043 and p = 0.02, respectively).</p><p><strong>Conclusion: </strong>Increased baseline EPC values seem to be a useful biomarker for the prediction of prognosis and tumor response in LC patients. Furthermore, high EPC levels at diagnosis might be an indicator of tumor growth and longer survival in LC patients.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 5","pages":"544-557"},"PeriodicalIF":1.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monte Carlo methods to assess biological response to radiation in peripheral organs and in critical organs near the target.","authors":"Natalia Matuszak, Igor Piotrowski, Marta Kruszyna-Mochalska, Agnieszka Skrobala, Mirosława Mocydlarz-Adamcewicz, Julian Malicki","doi":"10.5603/rpor.103525","DOIUrl":"https://doi.org/10.5603/rpor.103525","url":null,"abstract":"<p><strong>Background: </strong>The biological effects and clinical consequences of out-of-field radiation in peripheral organs can be difficult to determine, especially for low doses (0.1 Gy-1 Gy). In recent years, Monte Carlo (MC) methods have been proposed to more accurately predict nontarget doses. The aim of the present study was to assess the feasibility of using Monte Carlo methods to predict the biological response of tissues and critical organs to low dose radiation (0.1 to 1 Gy) based on results published in the literature.</p><p><strong>Materials and methods: </strong>Literature review, including studies published by our group.</p><p><strong>Results and conclusions: </strong>It has long been assumed that radiation doses to peripheral organs located far from the target volume are too low to have any clinical impact. In recent years, however, concerns about the risk of treatment-induced secondary cancers, even in peripheral organs, have continued to grow in line with increasing life expectancy. At present, it is difficult in routine calculations to accurately determine radiation doses to the whole body and peripheral organs. Moreover, the potential clinical impact of these doses remains uncertain and the biological response to low dose radiation depends on the organ. In this context, MC methods can predict biological response in those organs. Monte Carlo methods have become a powerful tool to better predict the consequences of interactions between ionising radiation and biological matter. MC modelling can also help to characterise microscopic system dynamics and to provide a better understanding of processes occurring at the cellular, molecular, and nanoscales.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 5","pages":"638-648"},"PeriodicalIF":1.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of MLC error on dose distribution in SRS treatment of single-isocenter multiple brain metastases: comparison between DCAT and VMAT techniques.","authors":"Hiroki Katayama, Takuya Kobata, Motonori Kitaoka, Shigeo Takahashi, Toru Shibata","doi":"10.5603/rpor.102616","DOIUrl":"https://doi.org/10.5603/rpor.102616","url":null,"abstract":"<p><strong>Background: </strong>Dynamic conformal arc therapy (DCAT) and volumetric modulated arc therapy (VMAT) can achieve near equal plan quality in single-isocenter multiple target stereotactic radiosurgery (SRS) for brain metastases. This study aimed to investigate the impact of multi-leaf collimator (MLC) errors during beam delivery on the dose distribution for each technique.</p><p><strong>Materials and methods: </strong>A 10-mm diameter delineation of the three targets was employed on the computed tomography images of a head phantom, and the reference plans were created using the DCAT and VMAT. We simulated the systematic opened and closed MLC errors. 10 MLC error plans with different magnitudes of errors were created in each technique. We investigated the relationship between the magnitude of MLC errors and the change in dose-volume histogram parameters of the targets and normal brain tissue.</p><p><strong>Results: </strong>The percentage change in the D_98% (Gy) and D_0.1% (Gy) of the target per millimeter of the MLC errors were 13.3% and 2.7% for the DCAT and 15.3% and 9.3% for the VMAT, respectively. The fluctuations of the maximum dose were very small for the DCAT compared to the VMAT. Changes in the V_12Gy (cc) of the normal brain tissue were 47.1%/mm and 53.2%/mm for the DCAT and VMAT, respectively, which are comparable changes for both techniques.</p><p><strong>Conclusions: </strong>Although the impact of MLC errors on the target coverage and the normal brain tissue is comparable for both techniques, the internal dose of the targets generated by the DCAT technique is robust to the MLC errors.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 5","pages":"531-543"},"PeriodicalIF":1.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can the reprogrammed cancer cells serve as an alternative source of (induced) cancer stem cells?","authors":"Ewelina Stelcer, Małgorzata Blatkiewicz, Karol Jopek, Wiktoria Maria Suchorska, Marcin Rucinski","doi":"10.5603/rpor.102821","DOIUrl":"https://doi.org/10.5603/rpor.102821","url":null,"abstract":"<p><strong>Background: </strong>Cancer stem cells (CSCs) constitute a small and elusive subpopulation of cancer cells within a tumor mass and are characterized by stem cell properties. Reprogrammed CSCs exhibit similar capability to initiate tumor growth, metastasis, and chemo- and radio-resistance and have similar gene profiles to primary CSCs. However, the efficiency of cancer cell reprogramming remained relatively low. There is limited literature available on the reprogramming of lung cancer cells. Hence, in this study we have conducted reprogramming of human lung cancer cells towards more benign type of cells.</p><p><strong>Materials and methods: </strong>The reprogramming process was carried out with the use of STEMCCA vector. We have investigated the gene expression profile of induced CSCs (iCSCs) using the microarray technique.</p><p><strong>Results: </strong>The lung iCSCs demonstrate morphology characteristics of induced pluripotent stem cells (iPSCs) and gene expression profile that significantly differ from cells before reprogramming. We have also presented the elevated level of expression of genes associated with the cancer stemness and thus revealed new interesting CSC-like molecular markers.</p><p><strong>Conclusions: </strong>These preliminary results demonstrated that the reprogramming process <i>in vitro</i> leads to the remarkable changes in cells at the gene level and has potential to be an alternative method of generating CSC-like cells.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 5","pages":"651-656"},"PeriodicalIF":1.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of National Comprehensive Cancer Network Guidelines Inclusion of Level 1 Evidence on Insurance Denial for Randomized Controlled Trial Patients with Metastatic Spine Disease.","authors":"Ulysses G Gardner, Melissa M Brately, Raed J Zuhour, Yilun Sun, Daniel E Spratt, Shearwood McClelland","doi":"10.5603/rpor.102822","DOIUrl":"https://doi.org/10.5603/rpor.102822","url":null,"abstract":"<p><strong>Background: </strong>The primary treatment of metastatic spine disease is radiation therapy (RT), traditionally conventional external beam RT (EBRT) or stereotactic body RT (SBRT). Until recently, there had been no Level 1 evidence supporting SBRT over EBRT, which has led to difficulties obtaining insurance approval. Publication of the first randomized controlled trial (RCT) comparing SBRT to EBRT for spine metastases [Canadian Cancer Trials Group (CCTG)] helped change this. The results showed superiority of SBRT in pain response; however, the results were not cited by The National Comprehensive Cancer Network (NCCN) until March 24, 2023. We present results from an ongoing RCT to assess the impact of this NCCN inclusion on insurance denials for trial-eligible patients.</p><p><strong>Materials and methods: </strong>The ongoing SPORTSMEN RCT randomizes metastatic spine cancer patients to SBRT versus EBRT. Trial-eligible patients during the first six months were examined to assess if SBRT was denied by insurance before March 24, 2023, versus afterwards. Fisher's exact test was used to assess for statistical significance.</p><p><strong>Results: </strong>Prior to CCTG NCCN inclusion, 25% of 12 trial-eligible patients experienced SBRT insurance denial. Following NCCN inclusion, of 8 patients, one (12.5%) has undergone insurance denial of SBRT. These differences were not statistically significant.</p><p><strong>Conclusions: </strong>The inclusion of Level 1 evidence in the NCCN guidelines has resulted in a numerical halving of spine SBRT insurance denials on a RCT, with the small sample size likely the largest culprit of not meeting statistical significance. These findings illustrate the importance of generating high-quality evidence, followed by timely inclusion into the NCCN guidelines.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 5","pages":"657-660"},"PeriodicalIF":1.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An omics-based tumor microenvironment approach and its prospects.","authors":"Rajeev Nema","doi":"10.5603/rpor.102823","DOIUrl":"https://doi.org/10.5603/rpor.102823","url":null,"abstract":"<p><p>Multi-omics approaches are revolutionizing cancer research and treatment by integrating single-modality omics methods, such as the transcriptome, genome, epigenome, epi-transcriptome, proteome, metabolome, and developing omics (single-cell omics). These technologies enable a deeper understanding of cancer and provide personalized treatment strategies. However, challenges such as standardization and appropriate methods for funneling complex information into clinical consequences remain. The tumor microenvironment (TME) is a complex system containing cancer cells, immune cells, stromal cells, and secreted molecules. To overcome these challenges, researchers can establish standardized protocols for data collection, analysis, and interpretation. Collaborations and data sharing among research groups and institutions can create a comprehensive and standardized multi-omics database, facilitating cross-validation and comparison of results. Multi-omics profiling enables in-depth characterization of diversified tumor types and better reveal their function in cancer immune escape. Datasets play a fundamental role in multi-omics approaches, with artificial intelligence and machine learning (AI) rapidly advancing in multi-omics for cancer.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 5","pages":"649-650"},"PeriodicalIF":1.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698559/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}